| Literature DB >> 22179162 |
Dirceu Solé1, Inês Cristina Camelo-Nunes, Gustavo F Wandalsen, Nelson A Rosário, Emanuel C Sarinho.
Abstract
BACKGROUND: Asthma and rhinitis often coexist, which potentially increases the disease severity and can negatively impact a patients' quality of life. However, there are few reports based on data obtained from the International Study of Asthma and Allergies in Childhood examining asthma severity in combination with rhinitisrelated symptoms.Entities:
Mesh:
Year: 2011 PMID: 22179162 PMCID: PMC3164407 DOI: 10.1590/s1807-59322011000900012
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Prevalence of current asthma, current rhinitis, and current rhinoconjunctivitis in Brazilian adolescents from ISAAC Phase Three centers, based on responses to the ISAAC written questionnaire (determined with Spearman's correlation coefficient).
| Center | n | Currentasthma (%) | Current rhinitis (%) | Current rhinoconjunctivitis (%) |
| Manaus | 3,009 | 18.1 | 23.0 | 12.8 |
| Caruaru | 3,026 | 17.9 | 25.5 | 15.4 |
| Aracaju | 3,041 | 18.7 | 25.6 | 17.4 |
| Feira de Santana | 1,732 | 21.5 | 33.0 | 17.2 |
| Salvador | 3,020 | 24.6 | 44.2 | 24.4 |
| Vitória da Conquista | 1,679 | 30.5 | 39.8 | 24.4 |
| Brasília | 3,009 | 19.7 | 29.3 | 15.4 |
| Nova Iguaçu | 3,185 | 11.8 | 17.4 | 8.9 |
| São Paulo West | 3,181 | 21.9 | 30.1 | 19.8 |
| São Paulo South | 3,161 | 18.7 | 27.4 | 12.2 |
| Santo André | 3,232 | 23.2 | 28.4 | 13.8 |
| Curitiba | 3,628 | 18.9 | 39.2 | 17.2 |
| Itajaí | 2,737 | 12.3 | 22.1 | 12.9 |
| Porto Alegre | 3,007 | 18.2 | 32.1 | 15.9 |
| Santa Maria – rural | 3,057 | 15.3 | 20.6 | 9.6 |
| Santa Maria – urban | 3,066 | 16.7 | 24.3 | 11.4 |
Spearman's correlation coefficient:
Current asthma current rhinitis: rs = 0.82 (95%CI: 0.60–0.93), p<0.0001.
Current asthma vs. current rhinoconjunctivitis: rs = 0.75 (95%CI: 0.47–0.89), p<0.0001.
Odds ratio (OR) and 95% confidence interval (95% CI) for wheezing-related symptoms in Brazilian adolescents with current rhinitis from ISAAC Phase Three centers.
| Center | Wheezing last yearOR (95%CI) | >12 wheezing episodes last yearOR (95%CI) | Sleep disturb.last yearOR (95%CI) | Speech problemslast yearOR (95%CI) | Asthma everOR (95%CI) | Wheezing with exercise last year OR (95%CI) | Nocturnal coughinglast yearOR (95%CI) |
| 4.18 (3.43–5.09)* | 2.41 (1.02–5.69)* | 1.58 (1.12–2.21)* | 2.37 (1.57–3.55)* | 1.82 (1.49–2.22)* | 2.92 (2.40–3.54)* | 3.56 (2.98–4.26)* | |
| 3.30 (2.72–4.01)* | 1.06 (0.46–2.44) | 1.44 (1.03–2.02)* | 1.37 (0.89–2.11) | 2.45 (2.03–2.97)* | 3.12 (2.56–3.80)* | 3.05 (2.57–3.61)* | |
| 3.03 (2.50–3.70)* | 1.61 (0.59–4.39) | 0.99 (0.71–1.37) | 0.83 (0.56–1.23) | 2.56 (2.08–3.14)* | 2.38 (1.93–2.83)* | 3.07 (2.60–3.64)* | |
| 3.67 (2.90–4.66)* | 6.93 (1.58–30.5)* | 1,81 (1.19–2.74)* | 1.35 (0.81–2.24) | 2.08 (1.53–2.82)* | 2.94 (2.40–3.65)* | 3.46 (2.80–4.28)* | |
| 3.80 (3.18–4.53)* | 0.68 (0.33–1.44) | 1.71 (1.23–2.37)* | 1.57 (1.03–2.40)* | 2.47 (2.00–3.06)* | 3.25 (2.78–3.80)* | 3.24 (2.77–3.80)* | |
| 3.47 (2.80–4.30)* | 2.90 (0.82–10.32) | 1.71 (1.19–2.45)* | 1.75 (1.11–2.75)* | 3.44 (2.55–4.63)* | 3.16 (2.57–3.88)* | 3.13 (2.55–3.85)* | |
| 3.67 (3.05–4.43)* | 3.96 (1.12–14.1)* | 1.85 (1.33–2.57)* | 1.59 (1.01–2.52) | 2.42 (1.97–2.97)* | 2.77 (2.31–3.33)* | 4.25 (3.60–5.02)* | |
| 4.36 (3.44–5.52)* | 2.35 (0.80–6.90) | 4.45 (3.31–5.99)* | 5.18 (3.46–7.75)* | 2.97 (2.22–3.98)* | 3.00 (2.40–3.70)* | 4.50 (3.70–5.49)* | |
| 3.75 (3.14–4.46)* | 8.03 (2.95– 21.8)* | 3.36 (2.75– 4.12)* | 4.27 (3.11–5.84)* | 2.77 (2.16–3.54)* | 3.18 (2.65–3.81)* | 3.49 (2.98–4.09)* | |
| 2.91 (2.42–3.51)* | 1.69 (0.71–4.02)* | 1.56 (1.12–2.18)* | 1.70 (1.02–2.85) | 2.50 (1.97–3.14)* | 2.40 (1.98–2.90)* | 3.37 (2.87–3.97)* | |
| 3.32 (2.80–3.94)* | 2.62 (1.08–6.40)* | 1.61 (1.21–2.16)* | 1.59 (1.03–2.45)* | 2.28 (1.78–2.91)* | 2.53 (2.10–3.05)* | 3.30 (2.81–3.87)* | |
| 2.19 (1.85–2.59)* | 1.68 (0.71–3.99) | 1.93 (1.41–2.66)* | 2.24 (1.45–3.47)* | 2.40 (1.91–3.02)* | 2.52 (2.13–2.98)* | 2.99 (2.59–3.44)* | |
| 3.94 (3.11–4.99)* | 1.83 (0.92–3.64) | 0.92 (0.60–1.42) | 0.72 (0.39–1.35) | 3.25 (2.54–4.17)* | 3.16 (2.56–3.90)* | 3.86 (3.20–4.67)* | |
| 3.65 (3.02–4.43)* | 1.70 (1.04–2.76)* | 1.93 (1.37–2.73)* | 1.19 (0.77–1.85) | 2.40 (2.00–2.87)* | 2.88 (2.41–3.44)* | 3.31 (2.82–3.89)* | |
| 3.74 (3.03–4.62)* | 2.76 (1.30–5.86)* | 1.15 (0.79–1.66) | 2.20 (1.35–3.59)* | 2.61 (2.12–3.22)* | 2.78 (2.29–3.37)* | 3.83 (3.22–4.55)* | |
| 3.59 (2.94–4.38)* | 2.07 (1.16–3.71)* | 1.82 (1.28–2.58)* | 1.82 (1.12–3.00)* | 2.92 (2.30–3.71)* | 2.72 (2.23–3.33)* | 3.95 (3.29–4.74)* |
l *p<0.05.
Odds ratio (OR) and 95% confidence interval (95% CI) for wheezing-related symptoms in Brazilian adolescents from ISAAC Phase Three centers with current rhinoconjunctivitis.
| Center | Wheezing last yearOR (95%CI) | >12 wheezing episodes last year OR (95%CI) | Sleep disturb.last yearOR (95%CI) | Speech problemslast yearOR (95%CI) | Asthma everOR (95%CI) | Wheezing from exercise last year OR (95%CI) | Nocturnal coughinglast yearOR (95%CI) |
| 4.63 (3.68–5.83) | 2.57 (1.15–5.76) | 1.57 (1.09–2.27) | 3.06 (2.03–4.61) | 2.02 (1.60–2.57) | 3.38 (2.69–4.25) | 4.08 (3.22–5.17) | |
| 3.21 (2.58–4.00) | 1.48 (0.63–3.50) | 1.38 (0.96–1.98) | 2.57 (1.66–3.99) | 2.44 (1.96–3.03) | 3.24 (2.60–4.04) | 3.20 (2.60–3.92) | |
| 2.93 (2.37–3.61) | 2.15 (0.80–5.84) | 1.61 (1.13–2.29) | 1.33 (0.89–2.01) | 2.50 (2.00–3.12) | 3.24 (2.63–3.98) | 3.98 (3.25–4.86) | |
| 3.73 (2.85–4.87) | 2.19 (0.87–5.55) | 1.52 (0.99–2.33) | 1.35 (0.81–2.24) | 2.18 (1.54–3.08) | 3.13 (2.42–4.04) | 3.96 (3.05–5.13) | |
| 3.40 (2.84–4.07) | 1.33 (0.64–2.77) | 1.87 (1.39–2.52) | 1.65 (1.14–2.38) | 2.21 (1.80–2.75) | 2.93 (2.47–3.48) | 3.12 (2.63–3.71) | |
| 3.18 (2.52–4.01) | 4.67 (1.48–14.69) | 2.88 (2.00–4.16) | 2.10 (1.38–3.22) | 2.83 (2.11–3.80) | 2.77 (2.20–3.48) | 2.92 (2.32–3.67) | |
| 4.11 (3.32–5.08) | 4.56 (1.56–13.33) | 1.84 (1.30–2.60) | 2.75 (1.74–4.33) | 2.60 (2.05–3.29) | 3.30 (2.67–4.09) | 3.77 (3.05–4.65) | |
| 6.04 (4.58–7.97) | 3.68 (1.16–11.6) | 5.41 (3.88–7.54) | 7.18 (4.71–10.90) | 4.20 (3.00–5.80) | 4.00 (3.00–5.25) | 5.45 (4.15–7.17) | |
| 3.62 (2.99–4.37) | 8.85 (3.59– 21.8) | 3.80 (3.07–4.68) | 5.47 (4.02–7.44) | 2.79 (2.15–3.60) | 3.27 (2.69–3.97) | 3.73 (3.11–4.47) | |
| 4.17 (3.32–5.23) | 1.49 (0.61–3.61) | 2.09 (1.45–3.01) | 2.31 (1.38–3.89) | 2.94 (2.23–3.87) | 3.23 (2.55–4.08) | 4.83 (3.85–6.05) | |
| 3.70 (3.00–4.56) | 3.17 (1.40–7.20) | 2.04 (1.48–2.82) | 2.21 (1.42–3.42) | 2.88 (2.18–3.80) | 3.21 (2.57–4.00) | 3.93 (3.20–4.84) | |
| 2.73 (2.25–3.31) | 2.32 (1.02–5.24) | 1.74 (1.25–2.42) | 1.72 (1.13–2.61) | 2.72 (2.13–3.48) | 2.95 (2.44–3.57) | 2.79 (2.34–3.33) | |
| 4.71 (3.62–6.12) | 2.37 (1.20–4.70) | 1.27 (0.81–2.01) | 1.23 (0.65–2.32) | 3.91 (2.97–5.14) | 4.38 (3.44–5.57) | 3.83 (3.05–4.82) | |
| 4.18 (3.37–5.18) | 1.31 (0.82–2.10) | 1.65 (1.16–2.34) | 1.61 (1.04–2.49) | 2.71 (2.19–3.35) | 3.80 (3.09–4.70) | 4.19 (3.42–5.15) | |
| 4.32 (3.33–5.60) | 1.96 (0.93–4.15) | 1.43 (0.93–2.20) | 2.16 (1.30–3.62) | 3.18 (2.47–4.10) | 3.72 (2.94–4.72) | 3.93 (3.12–4.95) | |
| 5.26 (4.14–6.68) | 3.34 (1.88–5.94) | 2.14 (1.45–3.17) | 3.03 (1.85–4.95) | 2.94 (2.20–3.97) | 3.19 (2.47–4.11) | 3.58 (2.80–4.60) |
p<0.05.